Search

Your search keyword '"Giovanni Rindone"' showing total 5 results
Start Over Author "Giovanni Rindone"
5 results on '"Giovanni Rindone"'

1. Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib

Author

Francesca Palandri, Elena M. Elli, Giuseppe Auteri, Massimiliano Bonifacio, Giulia Benevolo, Florian H. Heidel, Simona Paglia, Malgorzata M. Trawinska, Costanza Bosi, Elena Rossi, Mario Tiribelli, Alessia Tieghi, Alessandra Iurlo, Nicola Polverelli, Giovanni Caocci, Gianni Binotto, Francesco Cavazzini, Eloise Beggiato, Daniela Cilloni, Caterina Tatarelli, Francesco Mendicino, Maurizio Miglino, Monica Bocchia, Monica Crugnola, Camilla Mazzoni, Andrea D. Romagnoli, Giovanni Rindone, Sara Ceglie, Alessandra D’Addio, Eleonora Santoni, Daniele Cattaneo, Daniela Bartoletti, Roberto M. Lemoli, Mauro Krampera, Antonio Cuneo, Gianpietro C. Semenzato, Roberto Latagliata, Elisabetta Abruzzese, Nicola Vianelli, Michele Cavo, Alessandro Andriani, Valerio De Stefano, Giuseppe A. Palumbo, and Massimo Breccia

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2023
Full Text
View/download PDF

2. Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID‐19 vaccine: A single‐center prospective observational study (NCT05074706)

Author

Elisa Bossi, Andrea Aroldi, Lorenza Maria Borin, Luisa Verga, Diletta Fontana, Federica Cocito, Beatrice Manghisi, Giovanni Rindone, Fabrizio Cavalca, Alessia Ripamonti, Monica Raggi, Sergio Maria Ivano Malandrin, Annalisa Cavallero, Laura Antolini, Diego Bonardi, Rocco Giovanni Piazza, and Carlo Gambacorti‐Passerini

Subjects
cellular immune response, COVID‐19, hematological disorders, mRNA vaccine, seroconversion, Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Abstract Hematological patients at higher risk of severe COVID‐19 were excluded from the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccine trials. In this single‐center observational prospective study (NCT05074706), we evaluate immune response in the hematological patients followed at the Hematological Division of San Gerardo Hospital, Monza (Italy) deemed to be severely immunosuppressed after vaccination with two doses of the BNT162b2 vaccine. Anti‐SARS‐CoV‐2 immunoglobulin G titers above the cutoff value of 33.8 BAU/ml were detected in 303 (80.2%) out of the 378 patients enrolled. Patients with lymphoproliferative disorders had a significant lower probability of immunization (43.2% vs. 88.4%, p

Published
2022
Full Text
View/download PDF

3. DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients

Author

Federica Malighetti, Giulia Arosio, Chiara Manfroni, Mario Mauri, Matteo Villa, Beatrice Manghisi, Elena Inzoli, Giovanni Rindone, Giovanni P. M. Zambrotta, Ivan Civettini, Veronica Guglielmana, Daniele Ramazzotti, Giovanni Giudici, Silvia Bombelli, Roberto Perego, Rocco Piazza, Luca Mologni, and Carlo Gambacorti-Passerini

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

4. A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas

Author

Giovanni Rindone, Andrea Aroldi, Elisa Bossi, Luisa Verga, Giovanni Zambrotta, Sara Tarantino, Rocco Piazza, Lara Mussolin, Roberto Chiarle, Carlo Gambacorti-Passerini, Rindone, G, Aroldi, A, Bossi, E, Verga, L, Zambrotta, G, Tarantino, S, Piazza, R, Mussolin, L, Chiarle, R, and Gambacorti-Passerini, C

Subjects
ALK, Crizotinib, Lymphoma, Hematology
Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results